RJA
MRSN

Raymond James & Associates’s Mersana Therapeutics MRSN Stock Holding History

Raymond James & Associates’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-777
Closed -$114K – 3995
2022
Q4 		$114K Buy
+777
New +$131K ﹤0.01% 3615

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Raymond James & Associates's MRSN Position: Q1 2023 in Review

Raymond James & Associates sold out of Mersana Therapeutics (MRSN) in Q1 2023, closing a stake of 777 shares — an estimated $114K sold.

Raymond James & Associates first reported a position in MRSN in Q4 2022 and held it in 1 quarter. The position peaked at $114K in Q4 2022. 157 funds tracked by Wall St. Rank hold MRSN as of Q1 2023.

  • Raymond James & Associates reported no remaining Mersana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 777 Mersana Therapeutics shares in Q1 2023, an estimated $114K.
  • Raymond James & Associates first reported a position in Mersana Therapeutics in Q4 2022 and held it in 1 quarter.
  • Raymond James & Associates's Mersana Therapeutics position peaked at $114K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.